Broderick Brian C lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 83,559 shares of the company’s stock after selling 1,180 shares during the quarter. Johnson & Johnson makes up 4.1% of Broderick Brian C’s holdings, making the stock its largest holding. Broderick Brian C’s holdings in Johnson & Johnson were worth $11,054,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in JNJ. Lau Associates LLC grew its position in shares of Johnson & Johnson by 12.8% during the 1st quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares in the last quarter. Lynch & Associates IN grew its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after buying an additional 841 shares in the last quarter. Burke & Herbert Bank & Trust Co. grew its position in shares of Johnson & Johnson by 2.6% during the 1st quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares in the last quarter. Oakbrook Investments LLC grew its position in shares of Johnson & Johnson by 7.4% during the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after buying an additional 9,375 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Johnson & Johnson during the 1st quarter worth $1,731,000. 65.90% of the stock is currently owned by institutional investors.
A number of equities analysts have recently issued reports on JNJ shares. UBS AG reissued a “buy” rating and set a $148.00 price target (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. BMO Capital Markets reissued a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 5th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $135.29.
In other news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Equities Focus and is owned by of Equities Focus. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.equitiesfocus.com/2017/09/24/johnson-johnson-jnj-is-broderick-brian-cs-largest-position.html.
Johnson & Johnson (JNJ) traded down 0.27% during midday trading on Friday, reaching $131.39. The company’s stock had a trading volume of 4,334,862 shares. The stock’s 50-day moving average price is $132.79 and its 200 day moving average price is $129.43. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm has a market capitalization of $352.65 billion, a PE ratio of 22.23 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.74 EPS. Equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.